

BioLight Announces Issuance of Israeli Patent for the IOptiMate™ Technology

Tel-Aviv, Israel, September 30, 2015 – BioLight Life Sciences Investments (**OTCQX: BLGTY, TASE: BOLT**) (“BioLight” or the “Company”), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today the Israel patent office has issued patent covering the core of the IOptiMate™ technology for a non-penetrating laser assisted filtration surgery technology for treating glaucoma.

The patent, which is owned by IOptima, one of BioLight’s subsidiaries, will be in effect at least until December 2029.

The patent joins the registration of patents in other territories worldwide.

The registration is subject to customary fee payment.